Today, BioPharma Dive is highlighting some notable clinical trial updates presented at the annual meeting of the European Society of Cardiology. Over the weekend, several large pharmaceutical and biotechnology companies released detailed study data on medicines for an array of different heart conditions.
Below are three notable datasets and a look at how they’re being interpreted by investors and analysts.
Cytokinetics’ stock sell-off
Cytokinetics claimed one of the bigger clinical trial victories in biotech this year when, in June, it disclosed that its drug Myqorzo succeeded in a Phase 3 trial in people with the “non-obstructive” form of the heart condition hypertrophic cardiomyopathy. That study made Myqorzo the first drug of its kind to prove beneficial against both forms of the condition, and separated it from Bristol Myers Squibb’s market leading medicine Camzyos.
On Friday, detailed data from that study were published in The New England Journal of Medicine and presented at ESC. Multiple Wall Street analysts claimed those findings reinforced Myqorzo’s potential — despite the disclosure of a possible safety concern that sank Cytokinetics’ stock price.
